Clinical Trials Logo

Myeloid Leukemia, Acute clinical trials

View clinical trials related to Myeloid Leukemia, Acute.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04943757 Recruiting - Clinical trials for Myelodysplastic Syndromes

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

PTBCy
Start date: January 21, 2021
Phase: Phase 2
Study type: Interventional

Prognosis of patients undergoing salvage allogeneic stem cell transplantation for refractory leukemia or other refractory myeloid malignanies is poor. One of the approaches to augment graft-versus-leukemia effect the use of post-transplantation bendamustine in graft-versus-host disease prophylaxis. Despite high frequency of responses and durable remissions after this approach majority of patients develop a serious complication - cytokine release syndrome, which can be life-threatening in some patients. On the other hand post-transplantation cyclophocphamide was reported to abort cytokine release syndrome that sometimes occurs after graft transfusion in patients after haploidentical graft transfusion. The aim of this study is to evaluate if the combination of post-transplantation bendamustine (PTB) and post-transplantation cyclophosphamide (PTCY) facilitates comparable graft-versus leukemia effect to PTB, but with better safety profile and reduced incidence of severe cytokine release syndrome.

NCT ID: NCT04678401 Recruiting - Clinical trials for Myelodysplastic Syndromes

IS-free Treg HaploHCT

Start date: January 12, 2021
Phase: Phase 1
Study type: Interventional

This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) receiving a haploidentical donor allogeneic hematopoietic stem cell transplant (HSCT). The names of the study interventions involved in this study are: - Radiation-Total Myeloid and Lymphoid Irradiation (TMLI - Chemotherapy (Fludarabine, Thiotepa, Cyclophosphamide plus Mesna) - Infusion of haplo Treg-enriched donor cells (experimental therapy) - Infusion of unmodified haplo donor T cells (includes cancer-fighting T effector cells) - Infusion of haplo donor CD34+ Peripheral Blood Stem Cells